Development of an Oral Form of Azacytidine: Triacetyl-5-Azacytidine
Figure 4
(a) Antileukemic activity of TAC and ACT in BDF1 mice bearing L1210 lymphocytic leukemia cells after 5 days of treatment with indicated concentrations of oral TAC or i.p. ACT. (b) Toxic effect as indicated by average weight loss of the same tumor bearing mice.
